RCKT
Income statement / Annual
Last year (2024), Rocket Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Rocket Pharmaceuticals, Inc.'s net income was -$258.75 M.
See Rocket Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.15 M
|
$426.00 K
|
$330.00 K
|
$204.00 K
|
$169.00 K
|
$45.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.15 M
|
-$426.00 K
|
-$330.00 K
|
-$204.00 K
|
-$169.00 K
|
-$45.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$171.24 M
|
$186.34 M
|
$165.57 M
|
$125.48 M
|
$106.38 M
|
$58.62 M
|
$53.27 M
|
$14.19 M
|
$31.99 M
|
$12.55 M
|
| General & Administrative Expenses |
$101.96 M
|
$73.32 M
|
$58.77 M
|
$41.77 M
|
$27.92 M
|
$17.53 M
|
$17.89 M
|
$12.54 M
|
$9.89 M
|
$7.84 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$101.96 M
|
$73.32 M
|
$58.77 M
|
$41.77 M
|
$27.92 M
|
$17.53 M
|
$17.89 M
|
$12.54 M
|
$9.89 M
|
$7.84 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$250.00 K
|
-$186.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$273.21 M
|
$259.66 M
|
$224.34 M
|
$167.25 M
|
$134.86 M
|
$75.90 M
|
$70.97 M
|
$26.74 M
|
$41.88 M
|
$20.40 M
|
| Cost And Expenses |
$273.21 M
|
$259.66 M
|
$224.34 M
|
$167.25 M
|
$136.00 M
|
$75.90 M
|
$70.97 M
|
$26.74 M
|
$41.88 M
|
$20.40 M
|
| Interest Income |
$18.22 M
|
$15.94 M
|
$3.89 M
|
$3.07 M
|
$2.15 M
|
$3.41 M
|
$1.69 M
|
$819.00 K
|
$443.00 K
|
$89.00 K
|
| Interest Expense |
$1.89 M
|
$1.88 M
|
$1.91 M
|
$5.89 M
|
$7.55 M
|
$4.78 M
|
$5.24 M
|
$3.58 M
|
$1.42 M
|
$1.23 M
|
| Depreciation & Amortization |
$9.38 M
|
$7.10 M
|
$6.27 M
|
$5.37 M
|
$1.15 M
|
$426.00 K
|
$330.00 K
|
$204.00 K
|
$169.00 K
|
$45.00 K
|
| EBITDA |
-$247.49 M |
-$236.62 M |
-$213.69 M |
-$157.81 M |
-$131.59 M |
-$71.14 M |
-$71.16 M |
-$26.74 M |
-$41.27 M |
-$20.26 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$14.46 M
|
$14.06 M
|
$2.48 M
|
-$1.82 M
|
-$3.70 M
|
-$1.12 M
|
-$3.36 M
|
-$2.76 M
|
-$975.00 K
|
-$47.59 M
|
| Income Before Tax |
-$258.75 M
|
-$245.60 M
|
-$221.86 M
|
-$169.07 M
|
-$139.70 M
|
-$77.27 M
|
-$74.52 M
|
-$29.50 M
|
-$42.85 M
|
-$67.98 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.97 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$258.75 M
|
-$245.60 M
|
-$221.86 M
|
-$169.07 M
|
-$146.67 M
|
-$83.23 M
|
-$74.52 M
|
-$29.50 M
|
-$42.85 M
|
-$67.98 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.73 |
-2.92 |
-3.26 |
-2.68 |
-2.52 |
-1.7 |
-1.89 |
-4.36 |
-6.41 |
-10.29 |
| EPS Diluted |
-2.73 |
-2.92 |
-3.26 |
-2.68 |
-2.52 |
-1.7 |
-1.89 |
-4.36 |
-6.41 |
-14.85 |
| Weighted Average Shares Out |
$94.81 M
|
$84.01 M
|
$68.15 M
|
$63.24 M
|
$55.38 M
|
$49.01 M
|
$39.38 M
|
$6.77 M
|
$6.68 M
|
$6.61 M
|
| Weighted Average Shares Out Diluted |
$94.81 M
|
$84.01 M
|
$68.15 M
|
$63.24 M
|
$55.38 M
|
$49.01 M
|
$39.38 M
|
$6.77 M
|
$6.68 M
|
$6.61 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
